Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Chapter from the book *Glaucoma - Basic and Clinical Concepts*
Downloaded from: http://www.intechopen.com/books/glaucoma-basic-and-clinical-concepts

Interested in publishing with InTechOpen?
Contact us at book.department@intechopen.com
Cyclodestructive Procedures

Sima Sayyahmelli and Rakhshandeh Alipanahi

From the Glaucoma Division, Tabriz Medical Sciences University, Tabriz, Iran

1. Introduction

Several methods used when an initial filtering procedure is not adequate to control the refractory glaucoma and when resumption of medical therapy, revision of original surgery, repeat filtering surgery at a new site, or aqueous shunt implantation is not successful; finally all cyclodestructive procedures reduce aqueous secretion by destroying part of the secretory ciliary epithelium portion of the ciliary body including cyclocryotherapy, contact and non-contact trans-scleral thermal lasers such as continuous-wave with the 1064-nm Nd:YAG, argon, and portable 810-nm semiconductor Diode laser.1-4 Cryotherapy, the original technique, is increasingly being supplanted by laser photocoagulation, originally with the 1064-nm Nd:YAG laser and lately with the portable 810-nm semiconductor Diode laser.2-3 An endoscopic laser delivery system has been advocated for use with cataract surgery or in pediatric, pseudophakic, or aphakic eyes. Use of the argon laser aimed at the ciliary processes through a goniolens is possible in a small percentage of patients. Transcleral diode laser cyclophotocoagulation (CPC) reducing aqueous secretion by destroying, is generally considered to be better tolerated and perhaps more effective than cyclocryotherapy, and it has a lower incidence of complications such as postoperative pain, inflammation, phthisis bulbi and retinal detachment, possibly because of better absorption of this wavelength by the pigmented tissues of the ciliary body. Diode laser cyclophotocoagulation (CPC) is often the choice treatment of IOP-lowering in painful blind eyes or in eyes unlikely to respond to other modes of therapy. Interventions methods such as retrobulbar alcohol injection, retrobulbar chlorpromazine injection, or enucleation are rarely performed now because of improved CPC techniques. Treatment of glaucoma in the pediatric population is frequently challenging and may require multiple surgical interventions. In the past it was used mainly in uncontrolled end-stage secondary glaucoma with minimal visual potential mainly to control pain. However it is now apparent that it can also be used in eyes with reasonably good vision which may be retained provided control of IOP is adequate. This section studies the indications, success rate and long term efficacy and complications of the cyclodestructive procedures in refractory glaucoma. Laser cycloablation is generally considered to be better tolerated and perhaps more effective than cyclocryotherapy.3,4 The most commonly used technique for cyclodestructive surgery is the transscleral approach, in which the destructive element must pass through conjunctiva, sclera, and ciliary musculature, before reaching and destroying the ciliary processes. These procedures have the advantages of being noninvasive and relatively quick and easy because of variable success in adults (34-92%) and significant postoperative pain and complications including phthisis and retinal detachment, transscleral neodymium:YAG (Nd:YAG) and Diode lasers are replacing
cyclocryotherapy as the preferred form of cyclodestruction in these eyes.\textsuperscript{5-7} The cyclophotocoagulation has a lower incidence of complications such as pain, postoperative inflammation and phthisis bulbi, possibly because of better absorption of this wavelength by the pigmented tissues of the ciliary body.\textsuperscript{7-9} Several methods of Diode laser photocoagulation have been reported to lower IOP and reduce pain in the eyes of refractory glaucoma.\textsuperscript{10-15} Diode cyclophotocoagulation and sequential tube shunt following primary tube shunt failure in childhood glaucoma showed similar efficacy and complication rates. Ten to fifty percent of patients with primary congenital glaucoma fail goniotomy surgery and require further surgical intervention. Childhood glaucoma associated with systemic or ocular anomalies and secondary glaucoma such as that associated with congenital aphakia or pseudophakia have a worse surgical prognosis compared to primary congenital glaucoma. Trabeculectomy surgery with adjunctive mitomycin has a lower chance of successful control of children less than two years of age and in children who have had congenital cataract surgery. Additionally, compared to adults, the adjunctive use of anti-fibrotic agents with trabeculectomy in children may be associated with greater risk of late bleb-related infections. When a tube shunt fails to adequately control the intraocular pressure, limited treatment options remain. These options include a sequential tube shunt in another quadrant of the eye revision or replacement of the existing tube shunt, or a cyclodestructive procedure (usually transscleral or endoscopic Diode cyclophotocoagulation or cyclocryotherapy). Both tube shunts and transscleral Diode cyclophotocoagulation have been examined for treatment of refractory pediatric glaucoma. Compare the results of Contact Diod Laser Cyclophotocoagulation Versus Cyclocryotherapy in Refractory Glaucoma.\textsuperscript{10-15}

Ciliary ablation is indicated to lower IOP in eyes that have glaucoma resistant to conventional medical and surgical therapies (refractory glaucoma, neovascular glaucoma, congenital glaucoma, secondary glaucoma, Post-surgical glaucoma, poor visual potential or that are poor candidates for incisional surgery (because of the small risk of sympathetic ophthalmia), painful blind eyes or in eyes unlikely to respond to other modes of therapy were treated with transscleral Diode laser Cyclophotocoagulation (CPC).

Ciliary ablation is relatively contraindicated in eyes with good vision because of the risk of loss of visual acuity.
Preoperative evaluation is the same as for incisional glaucoma surgery.

2. Methods and considerations

All patients signed an informed consent for the Ciliary body ablation procedures, after an explanation of the risks and benefits. Cyclophotocoagulation was performed under local anaesthesia (A sub-Tenon or peri bulbar ) with the Laser settings arc 1.5-2 sec and 1500-2000 mW with semiconductor Diode laser system (810 nm laser wavelength) with a spherical polished tip oriented by a handpiece, “G-Probe.”. Figures 1 and 2. Duration was set at 2000 ms (2 seconds), and the initial power setting was 1750 MW. After the edge of the probe is aligned with the limbus, approximately 17-19 applications are placed 270° around the limbus, with a power of 1.5-2 W and a duration of approximately 2 seconds. The power was increased in 250 MW increments to a maximum of 2000 MW until an audible ‘popping’ sound is heard, and then the power was reduced by 250 MW to just below that level. Approximately 2-40 burns arc (typically five per quadrant for 270 degrees of treatment) placed 1.2 mm posteriorly to the limbus over 180 ° but avoiding the posterior ciliary nerves.
at 3 and 9 o'clock. In all cases, the probe tips were carefully examined. The Diode laser handpiece attachment from one manufacturer is shown in figure 2. A strong topical steroid is prescribed hourly on the day of treatment and then q.i.d. for 2 weeks. Oral non-steroidal anti-inflammatory agents are prescribed for 2 days. Figure 1 showed cyclodestructive procedures to relieve pain. Figure 2 showed Semiconductor Diode laser. Figure 3 showed “G probe” handpiece for contact Diode TCP.

Fig. 1. Cyclodestructive procedures to relieve pain

Fig. 2. Semiconductor Diode laser (IRIS Oculight SLx, Iris Medical Inc) for Diode contact TCP

Fig. 3. Showed “G probe” handpiece for contact Diode TCP

Frequently more than one treatment session is required for adequate pressure control. The outcome of cycloDiode therapy was determined in terms of:

1. Success rate: defined as the percentage of eyes achieving an IOP between 5 and 21 mm Hg with or without topical medication with cessation of oral carbonic anhydrase inhibitor use in all eyes after cycloDiode therapy at their final follow-up visit.
2. Response rate: defined as the percentage of patients achieving >30% drop from baseline IOP with cessation of oral carbonic anhydrase inhibitor use. This included eyes that developed hypotony (IOP<5mm Hg).

3. Failure rate: defined as percentage of patients who developed hypotony (IOP<5mm Hg) or phthisis, or those whose IOP drop was <30% from baseline.

The success rate is dependent on the type of glaucoma, frequently more than one treatment session is required for adequate pressure control and the procedure has to be repeated. Pain relief is generally good. After surgery intraocular pressure and mean number of antiglaucoma medications would be dropped.

Criteria for success included intraocular pressure (IOP) of 21 mmHg or less with no devastating complications or need for further glaucoma surgery.

Pain following these procedures may be substantial, and patients should be provided with adequate analgesics, including narcotics, during the immediate postoperative period.

Cyclophotocoagulation may be associated with vision loss, prolonged hypotony, pain, inflammation, cystoid macular edema, hemorrhage, and even phthisis bulbi. Sympathetic ophthalmia is a rare but serious complication. Mild postoperative pain and anterior segment inflammation are common. Serious complications are rare and include conjunctival burns, prolonged uveitis, hyphema, chronic hypotony, phthisis bulbi, scleral thinning, corneal decompensation and retinal or choroidal detachment. However, since the aim of the procedure is usually to relieve pain. Vision-threatening complications do not have the same significance as those following conventional filtering procedures.

Transscleral Diode laser cycloablation is a recognized therapeutic approach to refractory glaucoma that involves photocoagulation of the pars plicata of the ciliary body with consequent reduction of aqueous secretion. Diode laser cyclophotocoagulation appeared to be an effective and safe primary surgical treatment of medically uncontrolled chronic angle closure glaucoma, with intraocular pressure lowering effect persisting for up to two years.

TSCPC has a significant ocular hypotensive effect on glaucoma refractory to both tube shunt and medical therapy. An unqualified success after cycloablation would be the attainment of a target IOP without the need for further medication, coupled with preservation of visual function. CycloDiode therapy appears to be effective in lowering IOP, in both the short and long term.

Endoscopic cyclophotocoagulation (ECP) was introduced as an alternative to trans-scleral cyclophotocoagulation for treating refractory glaucomas in order to minimise complications such as phthisis and hypotony by providing direct visualisation of the ciliary processes. Glaucoma following penetrating keratoplasty, which has an incidence ranging from 10–52%, often proves refractory to medical treatment. We introduce a case of refractory post-PKP glaucoma in order to demonstrate the efficacy of ECP in treating post-PKP glaucoma and to describe its potential delayed effect in achieving intraocular pressure control.
describe its potential delayed effect in achieving intraocular pressure control Diode Laser Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Medically Uncontrolled Chronic Angle Closure Glaucoma Long-Term Clinical Outcomes Diode Laser Transscleral Cyclophotocoagulation for Refractory Glaucoma.\textsuperscript{18}

Contact Diode laser transscleral cyclophotocoagulation is useful in eyes with refractory glaucoma in which the risks of outflow surgery are deemed unacceptable. Diode laser transscleral cyclophotocoagulation (DCPC) is one of the most widely used methods of ciliary body ablation, with reported success rates ranging from 40% to 80% cyclodestructive procedures are generally reserved for eyes with glaucoma refractory to other forms of medical or surgical intervention. In the past 10 years, cyclocryotherapy has been replaced by other techniques, especially laser cyclophotocoagulation with Nd:YAG or Diode laser systems,\textsuperscript{5–10} that achieve good results with a lower complication rate.\textsuperscript{19–24} Diode laser transscleral cyclophotocoagulation is effective in lowering the intraocular pressure in chronic angle-closure glaucoma and its effect lasts for at least 1 year.\textsuperscript{20} Transscleral Diode laser cyclophotocoagulation is an effective and safe method for the treatment of advanced, refractory glaucoma. However, repeated treatments are often necessary. Success of treatment depends on the age of patients, previous surgery, and the type of glaucoma.\textsuperscript{21} Types of glaucoma that are often difficult to treat include neovascular glaucoma, posttraumatic glaucoma, glaucoma associated with aphakia severe congenital/developmental glaucoma, postretinal surgery glaucoma, glaucoma associated with penetrating keratoplasties, and glaucoma in eyes with scarred conjunctiva from surgery or disease processes.\textsuperscript{22} Delgado et al. (2003) reported that use of noncontact transscleral neodymium:yttrium-aluminum-garnet cyclophotocoagulation for NVG in 115 eyes, while providing long-term IOP reduction, was associated with complications that included inflammation, visual loss, and hypotony, and that repeat treatments may be necessary to main good control of IOP.\textsuperscript{27} Table 1 showed demographics and treatment results of Transscleral diode laser cyclophotocoagulation at the different studies.

<table>
<thead>
<tr>
<th>Reference</th>
<th>No. of eyes (%)</th>
<th>Age (yrs) (range)</th>
<th>Follow-up (mos)</th>
<th>Successfully treated eyes (%)</th>
<th>Reference number</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Mistlberger et al</td>
<td>93</td>
<td>9–92</td>
<td>12</td>
<td>74.2%</td>
<td>19</td>
</tr>
<tr>
<td>Mr J P Diamond et al</td>
<td>263</td>
<td>4–99</td>
<td>17</td>
<td>89%</td>
<td>15</td>
</tr>
<tr>
<td>Ness et al</td>
<td>32</td>
<td>22-92</td>
<td>17.1</td>
<td>28.6</td>
<td>17</td>
</tr>
<tr>
<td>Bloom et al</td>
<td>34</td>
<td>34.1</td>
<td>34.1</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Sood and Beck</td>
<td>9</td>
<td>1-15</td>
<td>12</td>
<td>66.7%</td>
<td>13</td>
</tr>
<tr>
<td>Jimmy et al</td>
<td>14</td>
<td>48-76</td>
<td>12</td>
<td>92.3%</td>
<td>16</td>
</tr>
<tr>
<td>T. Schlote et al.</td>
<td>93</td>
<td>9–92</td>
<td>12</td>
<td>74.2%</td>
<td>21</td>
</tr>
<tr>
<td>F. A. Hauber and W. J. Scherer</td>
<td>47</td>
<td>38–100</td>
<td>12</td>
<td>94.4%</td>
<td>24</td>
</tr>
<tr>
<td>Ataullah, Biswas, Artes, et al</td>
<td>53</td>
<td>6–90</td>
<td>23.1</td>
<td>84%</td>
<td>25</td>
</tr>
<tr>
<td>Iliev, Gerber</td>
<td>131</td>
<td>69-84</td>
<td>30.1</td>
<td>69.5%</td>
<td>26</td>
</tr>
</tbody>
</table>

Table 1. Demographics and treatment results of Transscleral diode laser cyclophotocoagulation at the different studies
Previous studies have demonstrated this, with ocular hypotensive responses.\textsuperscript{7-9} Our study showed that in 50.6\% of patients the IOP was below 21 mmHg. Complications of transscleral Diode CPC include conjunctival surface burns that may occur if tissue debris becomes coagulated on the tip and chars. We inspected all tips for this and found no debris. In addition, increased perimetal conjunctival pigmentation may occur. One of patients had hyptonia and phthisis after treatment 21 months after treatment. The risks of hyptonia and phthisis are directly proportional to the dosage of laser energy delivered in a treatment session,\textsuperscript{7} although, a clear relationship between treatment energy and IOP response, which is essential to accurate prediction of desirable effect, remains to be demonstrated. The published literature suggests that this type of treatment is usually reserved for eyes with end stage disease and poor visual potential. In conclusion, this study showed an increase of visual acuity after transscleral Diode laser cyclophotocoagulation therapy. Diode laser cyclophotocoagulation produces very characteristic injury to pars plicata, which frequently extends into pars plana, but with only mild persisting inflammation. Ciliary processes are, however, frequently spared within the treatment zone and may account for early or late treatment failure.\textsuperscript{22-24} Histopathological studies of enucleation specimens following laser cyclophotocoagulation (Diode and Nd:YAG laser) and cyclocryotherapy have been performed in humans \textsuperscript{25-29} and animals.\textsuperscript{12, 30-35} We have previously reported histopathology of two cases of clinical failure following Diode laser cyclophotocoagulation.\textsuperscript{36} This study examines histological outcomes in nine cases in humans, and correlates this with the clinical course in each eye.\textsuperscript{28} Repeated use of the G-probe in transscleral cyclophotocoagulation, with ethylene oxide sterilization in between, resulted in an average decrease of 3\% in laser energy delivered per repeated cycle of use up to the fourth cycle. No signs of physical damage were found.\textsuperscript{25-28} Laser G-probes remain functional after repeated use and ethylene oxide re-sterilization for up to four cycles. No visible physical damage to the probes was identified. It is safe and cost-effective to reuse G-probe for transscleral cyclophotocoagulation with ethylene oxide sterilization, provided the surgeon stays alert for signs of probe damage. This alertness should be retained regardless of whether new or old G-probes are used.\textsuperscript{29,30} We noticed microscopic contamination of the G-probe by the tear film fluid in all the probes examined by us. The review of literature indicates that repeated use of the G-probe is not uncommon. The types of techniques used for making it suitable for repeated use indicate that it is not universally recognized that the lumen of the G-probe can accumulate fluid during the procedure, which makes it potentially hazardous when used for other patients. Treatment with cyclophotocoagulation in patients with refractory glaucoma leads to increase in acuity and lower intraocular pressure. In our opinion the G-probe should not be reused as inadequately reprocessed G-probe can lead to risk of nosocomial infections, serious iatrogenic complications, and medico-legal problems.\textsuperscript{30} Underlying diagnosis of neovascular glaucoma is a significant risk factor for hypotony post TCP. Hypotony was defined as IOP <5 at the end of 1-year follow-up period. Factors, such as underlying diagnosis, total energy used, age, earlier operations, and retreatment rates, which may influence the development of hypotony were analyzed using univariate analysis.\textsuperscript{31-32} CycloDiode therapy is highly effective but there is a significant risk of hypotony, which may be reduced by applying lower energy in cases of very high pretreatment IOP and in neovascular glaucoma. The dose-response association remains unpredictable, although a linear relation was found for neovascular glaucoma. Cyclophotocoagulation is necessary in some intractable cases but should be avoided whenever possible because of its potential
adverse effects on the lens and the retina. Retrobulbar alcohol injection, retrobulbar chlorpromazine injection, or enucleation are rarely performed now because of improved CPC techniques.

3. References


[27] Hayreh S. Neovascular glaucoma. Prog Retin Eye Res. 2007 September; 26(5): 470–485 NVG is a severely blinding,


[31] Hla Myint Htoon, PhD,z Ching Lin Ho, MMed (Ophth), MMed(Paed), FRCS (Ed),*† Tin Aung, MMed (Ophth), FRCS(Ed), PhD,*†‡ and Shamira Perera, MBBS, BSc, FRCOphth Ramli N, Risk Factors for Hypotony After Transscleral Diode Cyclophotocoagulation, (J Glaucoma 2010;00:000–000)

This book addresses the basic and clinical science of glaucomas, a group of diseases that affect the optic nerve and visual fields and is usually accompanied by increased intraocular pressure. The book incorporates the latest development as well as future perspectives in glaucoma, since it has expedited publication. It is aimed for specialists in glaucoma, researchers, general ophthalmologists and trainees to increase knowledge and encourage further progress in understanding and managing these complicated diseases.

**How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following: